Our Approach:
Identify diseases with mTOR pathway driver mutations and strong evidence of mTOR involvement in pathology of disease
Target genomically defined subgroups across cancer types with mTOR pathway aberrations including TSC1, TSC2, and PTEN who are most likely to respond to mTOR treatment
Treat patients with nab-sirolimus (ABI-009), a potential best-in-class mTOR inhibitor leveraging the proven albumin-bound platform
